Biotech News

Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia

Arrowhead Pharmaceuticals (ARWR)Arrowhead PharmaceuticalsClinical readout

- Plozasiran reduced triglycerides (TG) by 79% and 81% versus placebo in SHASTA -3 and SHASTA -4 across the broad sHTG population - - More than 90% of plozasiran-treated patients achieved triglycerides below thresholds for AP risk, 500 mg/dL at Month 12, and more than half achieved triglycerides

Related news

ARWRArrowhead Pharmaceuticals2026-10-14 11:30 EST

Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers

ARWRArrowhead Pharmaceuticals2026-09-29 11:30 EST

Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies

RCKTRocket Pharmaceuticals2026-08-03 11:00 EST

Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease

RHHBYRoche Holdings AG2026-10-21 12:00 EST

Roche presents new pivotal trial data across broad neuroimmunology portfolio at MSToronto2026

TARAProtara Therapeutics2026-10-15 12:00 EST

Protara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral Support

BIIBBiogen2026-09-17 20:15 EST

Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN

PHVSPharvaris2026-09-08 10:50 EST

Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks

MNPRMonopar2026-11-02 13:00 EST

Monopar to Present at AASLD – The Liver Meeting® 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data

BIIBBiogen2026-10-02 15:20 EST

Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus

ABEOAbeona Therapeutics2026-11-09 11:30 EST

Abeona Therapeutics® Acquires Phase 3-Ready APT-1011, Now ABO-801, and Enters Into Agreement for $30 Million Private Placement

Arrowhead Pharmaceuticals

RNA Interference Platform Arrowhead Pharmaceuticals develops RNA interference medicines that silence disease-causing genes. Its delivery technologies support programs targeting the liver and other tissues. REDEMPLO REDEMPLO, or plozasiran, is an RNAi therapy targeting APOC3. It is approved in the United States to reduce triglycerides in...

Recent company news

Stock data

Close
43.65 USD
Market cap
9.98B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States